Elevation of the glycated albumin to glycated hemoglobin ratio during the progression of hepatitis C virus related liver fibrosis

Figure 1 The glycated albumin/glycated hemoglobin ratio in relation to the METAVIR fibrosis score in patients with hepatitis C virus-related chronic liver disease. The glycated albumin (GA)/glycated hemoglobin (HbA1c) ratio increased as the fibrosis progressed. There was a significant difference between the F0-F1 vs F4, F2 vs F4, and F3 vs F4 groups.

Figure 2 The glycated albumin/glycated hemoglobin ratio in patients with hepatitis C virus-related chronic liver disease. A: A comparison between the F0-F3 (no cirrhosis) group and F4 (cirrhosis) group. The glycated albumin (GA)/glycated hemoglobin (HbA1c) ratio was higher in patients with cirrhosis than that in non-cirrhotic patients; B: The comparison between the F0-F2 (no or intermediate fibrosis: without severe fibrosis) group and the F3-F4 (severe fibrosis) group. The GA/HbA1c ratio was higher in the patients with significant fibrosis than that in the patients with no or minimal fibrosis; C: A comparison between the F0-F1 (no or minimal fibrosis: without significant fibrosis) group and the F2-F4 (significant fibrosis) group. The GA/HbA1c ratio was higher in the patients with significant fibrosis than in those with either minimal fibrosis or none at all.